Mersana Therapeutics surged over 200% in premarket trading after Day One Biopharmaceuticals agreed to acquire the company for up to $285 million. The deal includes a $25-per-share cash tender offer, representing an 182% premium, plus a contingent value right worth up to $30.25. The acquisition is expected to close by January 2026.